NCT01907165 is a EARLY_PHASE1 clinical trial of Temozolomide in Glioblastoma, sponsored by Washington University School of Medicine.

Who is sponsoring NCT01907165?

NCT01907165 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT01907165?

Interventions in NCT01907165: Temozolomide, Disulfiram, Copper gluconate.

What condition does NCT01907165 study?

NCT01907165 studies Glioblastoma.

Is NCT01907165 still recruiting?

NCT01907165 is currently completed. Last updated 20 July 2018.

Last reviewed 2018-07-20 · How we verify

NCT01907165

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

Completed EARLY_PHASE1 Last updated 20 July 2018

What this trial tests

EARLY_PHASE1 trial testing Temozolomide in Glioblastoma in 21 participants. Completed in 9 February 2018.

Timeline

10 October 2013

Primary endpoint
10 November 2016

9 February 2018

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	10 October 2013
Primary completion	10 November 2016
Estimated completion	9 February 2018
Sites	1 location across United States

Drugs / interventions tested

Temozolomide (temozolomide) — full drug profile →
Disulfiram (DISULFIRAM) — full drug profile →
Copper gluconate — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Connecting copper and cancer: from transition metal signalling to metalloplasia.
Ge EJ, Bush AI, Casini A, Cobine PA, et al · · 2022 · cited 952× · PMID 34764459 · DOI 10.1038/s41568-021-00417-2
Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A, Bankhead A, Luesakul U, Muangsin N, et al · · 2018 · cited 612× · PMID 29669750 · DOI 10.1124/pr.117.014944
Cuproptosis: mechanisms and links with cancers.
Xie J, Yang Y, Gao Y, He J. · · 2023 · cited 510× · PMID 36882769 · DOI 10.1186/s12943-023-01732-y
Overcoming cancer therapeutic bottleneck by drug repurposing.
Zhang Z, Zhou L, Xie N, Nice EC, et al · · 2020 · cited 328× · PMID 32616710 · DOI 10.1038/s41392-020-00213-8
Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD, Byron SA, Tran NL, Phillips JJ, et al · · 2015 · cited 163× · PMID 25934816 · DOI 10.1093/neuonc/nov031
Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance.
Babak MV, Ahn D. · · 2021 · cited 125× · PMID 34440056 · DOI 10.3390/biomedicines9080852
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.
Weth FR, Hoggarth GB, Weth AF, Paterson E, et al · · 2024 · cited 112× · PMID 38012383 · DOI 10.1038/s41416-023-02502-9
Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors.
Rodriguez-Torres M, Allan AL. · · 2016 · cited 103× · PMID 26445849 · DOI 10.1007/s10585-015-9755-9

Verify or expand the search:

Other trials of Temozolomide

Trials testing the same drug.

NCT04373785 — NG101m Adjuvant Therapy in Glioblastoma Patients · Phase 1, PHASE2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07452458 — Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, ID · Phase 3 · not yet recruiting
NCT06639607 — PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/Hi · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01907165 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 20 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01907165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing